ArticleCureus2024
Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option. Objectives The primary objective was to assess the efficacy of the T-DM1 biosimilar by evaluating progression-free survival (PFS) and overall survival (OS). The secondary objective focused on analyzing the safety profile, including the incidence and characteristics of adverse events (AEs) during T-DM1 treatment. Materials and methods In this retrospective, single-center study, 30 HER2-positive breast cancer patients were treated with T-DM1 at a dose of 3.6 mg/kg, administered intravenously every 21 days. The primary outcomes measured were PFS, OS, time to treatment failure (TTF), complete response (CR), and partial response (PR). The secondary endpoint was the documentation of AEs. Results All patients, with a median age of 57 years, received prior HER2-targeted therapy, and five (16.6%) patients had undergone brain radiotherapy. CR was achieved in 20 (66.6%) patients, while 10 (33.3%) patients attained PR. PFS, OS, and TTF were approximately 14, 24, and 13 months, respectively. Common adverse events included elevated transaminases, anemia, and thrombocytopenia, the majority of which were controllable and reversible. Conclusion This study provides important insights into the efficacy and safety of the T-DM1 biosimilar. The findings indicate that T-DM1 is effective in enhancing OS and managing advanced HER2-positive breast cancer, including selective patients with brain metastases. The results highlight the T-DM1 biosimilar as a cost-effective treatment option with an expected safety and tolerability profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.